This clinical trial is focused on studying the treatment of Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study involves adult participants who have been newly diagnosed with this condition and have not responded optimally after undergoing a procedure called Autologous Stem Cell Transplantation (ASCT). The trial aims to compare the effectiveness and safety of a new treatment called Idecabtagene Vicleucel (also known as bb2121) combined with Lenalidomide maintenance therapy, against Lenalidomide maintenance therapy alone. Lenalidomide is a medication that helps to slow down or stop the growth of cancer cells, while Idecabtagene Vicleucel is a type of cell therapy that uses modified immune cells to target and destroy cancer cells.

Participants in the study will receive either the combination of Idecabtagene Vicleucel and Lenalidomide or Lenalidomide alone. The study will monitor the participants over a period to assess how well the treatments work in preventing the progression of the disease, which is referred to as Progression Free Survival (PFS). The trial will also look at other outcomes such as overall survival, the duration of response to the treatment, and any side effects experienced by the participants. The study is designed to provide valuable information on whether the combination therapy offers better outcomes compared to Lenalidomide alone.

The trial will involve regular check-ups and assessments to monitor the participants’ health and response to the treatment. Participants will receive the treatments through different methods, such as oral capsules for Lenalidomide and intravenous infusions for Idecabtagene Vicleucel. The study is expected to continue for several years to gather comprehensive data on the long-term effects and benefits of the treatments. This research is crucial in finding more effective ways to manage and treat Multiple Myeloma, especially for those who do not achieve the desired response from standard treatments.